Actagardin
(Synonyms: 阿肽加定,Antibiotic A 3802-IV-3,Gardimycin) 目录号 : GC10552
A tetracyclic lantibiotic
Cas No.:59165-34-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Actagardin is a tetracyclic antibiotic.
Actagardin is a tetracyclic antibiotic produced by several species of Actinoplanes.
In vitro: During the repeated fermentations of actagardin, two new compounds, named D and E, were isolated. Compound D was found to be twice as active as actagardin against Streptococcus pyogenes C 203 and four times more active than actagardin against Staphylococcus aureus ATCC 6538, S. pneumoniae UC 41, and S. aureus TOUR in the in-vitro tests [1].
In vivo: Animal study showed that compound D was also more effective than the parent compound actagardin against experimental infections in mice with either S. pyogenes C 203 or S. aureus TOUR, after sc administration. However, compound D was ineffective at doses up to 150 mg/kg when given orally to mice infected with S. pyogenes C 203. Moreover, compound D (LD50 1,250 mg/kg, mice, ip) was about 2.5 times more toxic than actagardine (3,310 mg/kg). In addition, compound E showed practically no in vitro activity up to 50 μg/ml against the tested organisms [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Malabarba A, Landi M, Pallanza R, Cavalleri B. Physico-chemical and biological properties of actagardine and some acid hydrolysis products. J Antibiot (Tokyo). 1985 Nov;38(11):1506-11.
| Cas No. | 59165-34-3 | SDF | |
| 别名 | 阿肽加定,Antibiotic A 3802-IV-3,Gardimycin | ||
| 化学名 | D-cysteinyl-L-serylglycyl-L-tryptophyl-L-valyl-L-cysteinyl-(2S,3S)-2-amino-3-mercaptobutanoyl-L-leucyl-(2S,3S)-2-amino-3-mercaptobutanoyl-L-isoleucyl-L-a-glutamyl-L-cysteinylglycyl-(2S,3S)-2-amino-3-mercaptobutanoyl-L-valyl-L-isoleucyl-L-cysteinyl-L-alany | ||
| Canonical SMILES | O=C(CN1)N[C@@H](CC2=CNC3=C2C=CC=C3)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H]([C@H](C)SC[C@](C(NCC(N[C@@]([C@@H]4C)([H])C(N[C@@H](C(C)C)C(N[C@@]5([H])[C@@H](C)CC)=O)=O)=O)=O)([H])NC6=O)C(N[C@@H](CC(C)C)C(N[C@](C(N[C@]([C@@H](C)CC)([H])C(N[C@H]6CCC(O)=O)=O)=O) | ||
| 分子式 | C81H124N20O24S4 | 分子量 | 1890.2 |
| 溶解度 | Soluble in ethanol;methanol;DMSO;dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.529 mL | 2.6452 mL | 5.2904 mL |
| 5 mM | 0.1058 mL | 0.529 mL | 1.0581 mL |
| 10 mM | 0.0529 mL | 0.2645 mL | 0.529 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet